Biomarin

15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
Flag link:
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
Yahoo/Zacks.com
M&A
Biomarin
Vertex Pharmaceuticals
Incyte
Alnylam
Alexion
Flag link:
Up on Deck! Ten Q3 Biotech Earnings Reports to Watch Next Week
Up on Deck! Ten Q3 Biotech Earnings Reports to Watch Next Week
BioSpace
earnings
biotech
Biogen
Alexion Pharmaceuticals
Bristol-Myers Squibb
Celgene
Gilead Sciences
Merck
Biomarin
Galapagos
Seattle Genetics
Dr Reddy's
Flag link:
3 Biotech Stocks With Virtual Monopolies
3 Biotech Stocks With Virtual Monopolies
Motley Fool
Alexion Pharmaceuticals
Biomarin
Vertex Pharmaceuticals
Flag link:
Express Scripts staking out million-dollar gene therapies
Express Scripts staking out million-dollar gene therapies
Reuters
Express Scripts
PBMs
gene therapies
drug pricing
Biomarin
Bluebird Bio
Spark Therapeutics
Flag link:
BioMarin Pharmaceutical Sets Its Sights on $2 Billion
BioMarin Pharmaceutical Sets Its Sights on $2 Billion
Motley Fool
Biomarin
earnings
Flag link:
BioMarin Begins Pediatric Study on Achondroplasia Candidate
BioMarin Begins Pediatric Study on Achondroplasia Candidate
Yahoo/Zacks.com
Biomarin
clinical trials
vosoritide
achrondoplasia
Flag link:
Two drugs in the pipeline representing unique marketing challenges
Two drugs in the pipeline representing unique marketing challenges
Medical Marketing and Media
valrox
Biomarin
hepatitis A
risankizumab
AbbVie
Boehringer Ingelheim
psoriasis
Flag link:
BioMarin Rises on Approval of Palynziq (pegvaliase-pqpz)
BioMarin Rises on Approval of Palynziq (pegvaliase-pqpz)
CP Wire
Biomarin
Palynziq
PKU
FDA
Flag link:
BioMarin Rises on Approval of Palynziq (pegvaliase-pqpz)
Biomarin
Palynziq
PKU
Flag link:
A Big Decision Is Fast-Approaching for This Rare-Disease Drugmaker
A Big Decision Is Fast-Approaching for This Rare-Disease Drugmaker
Motley Fool
Biomarin
pegvaliase
PKU
FDA
Flag link:
Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study
Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study
Endpoints
Biomarin
hemophilia A
valrox
Flag link:
BioMarin Cruises While It Waits on Seventh Approval
BioMarin Cruises While It Waits on Seventh Approval
Motley Fool
Biomarin
pegvaliase
FDA
PKU
earnings
Flag link:
8 Takeout targets to watch in 2018
8 Takeout targets to watch in 2018
BioPharma Dive
M&A
Allergan
Alnylam
Biomarin
Bristol-Myers Squibb
Incyte
Madrigal Pharmaceuticals
Spark Therapeutics
Sucampo
Flag link:
[video]ASH 2017 Recap: These Were the Big Winners and Losers
[video]ASH 2017 Recap: These Were the Big Winners and Losers
Motley Fool
ASH2017
Bluebird Bio
Juno Therapeutics
Spark Therapeutics
Biomarin
JNJ
Celgene
Flag link:
ASH 2017: What you missed
ASH 2017: What you missed
BioPharma Dive
ASH17
Biomarin
Spark Therapeutics
Gilead Sciences
Novartis
Juno Therapeutics
AbbVie
Roche
JNJ
Flag link:
5 Biotech Buyout Candidates for 2018
5 Biotech Buyout Candidates for 2018
Yahoo/Motley Fool
biotech
M&A
Biogen
Biomarin
Bluebird Bio
Geron
SAGE Therapeutics
Flag link:
ASH17: Spark gene therapy falls behind BioMarin in hemophilia
ASH17: Spark gene therapy falls behind BioMarin in hemophilia
BioPharma Dive
ASH17
Spark Therapeutics
gene therapy
Biomarin
hemophilia A
SPK-8011
Flag link:
ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia
ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia
BioPharma Dive
ASH17
Biomarin
gene therapy
hemophilia A
valoctocogene
Flag link:
How much is an FDA shortcut worth to drug developers hustling to an OK? Holding steady at $125M, cash
How much is an FDA shortcut worth to drug developers hustling to an OK? Holding steady at $125M, cash
Endpoints
FDA
priority review vouchers
Biomarin
Flag link:

Pages